TEVA, US8816242098

JPMorgan raises target for Teva stock to USD 50.00

Published on 10/15/2026 at 09:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Weltruza adds a once-monthly option in the United States after FDA approval on October 9, 2026. Teva stock enters its Q3 results date on November 3, 2026.

Pipeline timing and product launch

JPMorgan raised its target from USD 40.00 to USD 50.00 on October 12, 2026.
Weltruza received approval with three monthly dose strengths on October 9, 2026.
Teva expects to report third-quarter results on November 3, 2026.

TEVA, US8816242098, Illustration mit AI erstellt.

JPMorgan raised its Teva target from USD 40.00 to USD 50.00 on October 12, 2026, according to Yahoo Finance. The move followed Teva's FDA approval of Weltruza, a once-monthly injectable treatment for schizophrenia, on October 9, 2026. For investors, the key question is whether the new product can strengthen Teva's branded medicine portfolio.

Three milestones shape the story

Teva's chronology starts on September 23, 2026, when it published an aide memoire ahead of third-quarter results scheduled for 7:00 a.m. ET on November 3, 2026, as Teva stated. On October 9, the company announced FDA approval for Weltruza. On October 12, JPMorgan lifted its target from USD 40.00 to USD 50.00.

The FDA approval covers three monthly strengths of 318 mg, 425 mg and 531 mg, with no loading dose, oral supplementation or post-injection monitoring required, according to Teva Pharmaceutical Industries. The treatment is expected to launch in the United States in the coming weeks.

What does the next report test?

Teva reported USD 4.14 billion in revenue and a net loss of USD 576.00 million for the second quarter of 2026. Diluted earnings per share were negative USD 0.49 in that period, according to Yahoo Finance. Revenue was down 1.00 percent from the second quarter of 2025, while the loss contrasts with net income of USD 369.00 million in the first quarter of 2026.

Teva's next two dated investor events are the third-quarter report on November 3, 2026, followed by an R&D Day in New York on November 11, 2026, as listed by MarketBeat. The report will show whether Weltruza's approval is beginning to change the balance between Teva's generic medicines and branded growth products.

Company profile and listing

Teva Pharmaceutical Industries Limited is a global drug manufacturer focused on generic medicines, specialty pharmaceuticals, biosimilars and active pharmaceutical ingredients. Its listed securities trade on the NYSE and TASE under the ticker TEVA. The company operates in healthcare and its specialty portfolio includes CNS, respiratory and oncology treatments.